Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction
Conditions
Interventions
Tolterodine ER 4 mg QD
Tamsulosin 0.4 mg QD
Locations
95
United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Homewood, Alabama, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Culver City, California, United States
Pfizer Investigational Site
Fresno, California, United States
Start Date
November 1, 2004
Completion Date
May 1, 2006
Last Updated
January 27, 2021
NCT05362292
NCT07105150
NCT01953263
NCT06411158
NCT06706362
NCT05806164
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions